Ardigen published research from the University of Bonn and collaborating German institutes using RFdiffusion, ProteinMPNN, and structure-prediction models to design thousands of compact protein minibinders against cancer-associated surface targets including PD-L1, CD276, and VTCN1.

From complex data to AI-driven drug discovery insights Ardigen is an AI driven data-to-insights partner for life science organizations addressing the complexity of modern, multimodal drug discovery. We build AI-ready biomedical data foundations and reusable data products that support the full drug discovery and development lifecycle, from target identification through clinical and regulatory stages, across diverse therapeutic areas. Our work starts with biology: we align every analytical approach with scientific purpose, enabling our partners to ask better questions, extract more meaningful answers, and move faster from raw data to confident decisions. Whether structuring large-scale omics data, analyzing high-content imaging, or integrating clinical, phenotypic, and chemical profiles, we help drug discovery teams turn fragmented datasets into scalable, insight-driven workflows. What we deliver: - Multimodal data solutions tailored to therapeutic questions - Curated, interoperable data products designed for modeling and experimentation - Custom analytics and AI workflows grounded in scientific relevance Interpretation-ready outputs that accelerate decision-making and reduce R&D risk Why Ardigen: - Deep biological and computational expertise embedded in every solution - Modular delivery model aligned to your data maturity - Proven across 700+ discovery projects - Trusted by global leaders in pharma and biotech Let’s move from data complexity to discovery clarity - together.